Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

2104 - High-dose methotrexate (HD-MTX) as CNS prophylaxis significantly improves outcome in patients with high-risk diffuse large B-cell lymphoma (DLBCL)


09 Oct 2016


Haematological malignancies


Teresa Calimeri


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


T. Calimeri1, C. Cecchetti1, A. Vignati1, M. Sassone1, M. Foppoli1, L. Scarfò1, M. Ponzoni2, A. Ferreri1

Author affiliations

  • 1 Department Of Oncohematology, IRCCS San Raffaele, 20132 - Milano/IT
  • 2 Pathology Unit, IRCCS San Raffaele, 20132 - Milano/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2104


CNS dissemination is lethal in DLBCL. However, risk predictors and effective prophylaxis remain to be defined. Thus, we analysed the value of a risk-tailored CNS prophylaxis in a mono-institutional retrospective series of 242 pts with DLBCL in the rituximab era.


Consecutive HIV-neg adults with DLBCL treated with first-line R-CHOP or similar ± RT were considered. CNS dissemination risk was based on involvement of specific extranodal organs (testis, kidney/adrenal, spine, skull, paranasal sinuses, orbit, and/or breast) and/or International Prognostic Index (IPI) of 4-5. CNS prophylaxis, consisting of 3-4 cycles of MTX 3 g/m2 ± intrathecal chemotherapy (IT) was indicated in pts with high CNS recurrence risk diagnosed after 2007.


242 pts were analyzed (median age 66, range 18-89). CNS dissemination risk was low in 147 (61%) and high in 95 (39%). Prophylaxis was indicated in 47 high-risk pts: 36 pts received HD-MTX ± IT, 11 pts receive only IT due to MTHFR polymorphisms, comorbidity or old age. Unexpected toxicity and interruptions were not recorded. At a median follow-up of 51 months (12-171), 11 (4.5%) pts experienced CNS relapse: 6 in the parenchyma, the others in the meninges. CNS relapse rate was


HD-MTX-based prophylaxis is highly effective in DLBCL with increased risk of CNS recurrence defined by involvement of certain extranodal organs and/or high IPI score. The relevant OS effect of HD-MTX can be explained by the high mortality associated with CNS relapse; however, an influence on systemic disease control cannot be excluded.

Clinical trial identification

Legal entity responsible for the study

IRCCS San Raffaele Scientific Institute, Milan, Italy


IRCCS San Raffaele Scientific Institute, Milan, Italy


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings